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ABSTRACT Growth factors have been widely used in
strategies to regenerate and repair diseased tissues, but
current therapies that go directly from bench to bed-
side have had limited clinical success. We hypothesize
that engineering successful therapies with recombinant
proteins will often require specific quantitative infor-
mation of the spatiotemporal role of the factors and
the development of sophisticated delivery approaches
that provide appropriate tissue exposures. This hypoth-
esis was tested in the context of therapeutic angiogen-
esis. An in vitro model of angiogenesis was adapted to
quantify the role of the concentration/gradient of
vascular endothelial growth factor [VEGF(165)] on
microvascular endothelial cells, and a delivery system
was then designed, based on a mathematical model, to
provide the desired profile in ischemic mice hindlimbs.
This system significantly enhanced blood vessel forma-
tion, and perfusion and recovery from severe ischemia.
This general approach may be broadly applicable to
growth factor therapies. Chen, R. R., Silva, E. A., Yuen,
W. W., Brock, A. A., Fischbach, C., Lin, A. S., Guldberg,
R. E., Mooney, D. J. Integrated approach to designing
growth factor delivery systems. FASEB J. 21, 3896–3903
(2007)
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Current molecular-level understanding of pro-
cesses regulating tissue formation (e.g., angiogenesis)
suggests recombinant growth factors may provide dis-
ease therapies, but clinical efforts that go directly from
discovery to clinical application have often been unsuc-
cessful (1, 2). The success of therapeutic growth factor
delivery strategies may depend on the ability to intelli-
gently design delivery systems based on quantitative
delivery parameters.
Tissue development and regeneration depend on
tightly coordinated spatial and temporal growth factor
signals, and recombinant growth factors have been
widely proposed for therapeutic use in the regenera-
tion and repair of diseased tissues (3). Vascular endo-
thelial growth factor (VEGF) is a potent initiator of new
vascular network growth, termed angiogenesis (4), and
has been the centerpiece of many strategies to treat
ischemic diseases (1). However, delivery strategies thus
far have yielded limited success in creating stable,
functional vasculature capable of relieving local isch-
emia (5), and this likely relates both to the rapidly
depleted, poorly controlled local concentrations of
VEGF that result from the typical delivery route (2) and
the disorganized, poorly functional vessel networks
formed. Furthermore, although the absolute concentra-
tion and gradient of VEGF in vitro clearly regulate endo-
thelial cell phenotype and nascent angiogenesis, there is
little quantitative information regarding the specific phys-
iologically active concentration range and gradient. Suc-
cessful therapies using VEGF will likely require knowledge
of the cell exposure necessary to elicit a controlled
angiogenic response and the design of a VEGF delivery
system that can provide therapeutically effective growth
factor profiles based on these criteria.
Using a combination of quantitative in vitro methods,
we developed an in vitro model of angiogenesis to allow
the quantification of VEGF binding on human dermal
microvascular endothelial cells (MECs), used this in
vitro model to determine the concentration and gradi-
ent of VEGF presentation necessary to direct angiogen-
esis, and then designed a system capable of delivering
VEGF in vivo in the desired profile. Based on in vitro
evaluation of growth factor controlled angiogenesis, in
vivo delivery of growth factors was optimized to en-
hance recovery from severe ischemia. The approach we
describe may also lead to enhanced tissue integration
and function when applied to the regeneration of other
tissues such as bone or nerves.
MATERIALS AND METHODS
Cell culture
Dermal MECs were purchased from Cambrex (East Ruther-
ford, NJ, USA) and cultured to confluence at 37°C and 5%
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CO2 in EGM-2MV containing all supplements. MECs at P4
were used for all experiments.
Bead sprouting assay
This sprouting assay was adapted from previously described
methods (6). Briefly, swollen and sterilized dextran microcar-
riers (Amersham Biosciences, Piscataway, NJ, USA) were
washed in EGM-2MV and combined with MECs in a spinner
flask at a seeding density of 5000 cells/cm2. The flask was
alternated between stirring and nonstirring every 30 min and
incubated at 37°C and 5% CO2 to promote even cell attach-
ment (6, 7). After 4 h, the beads and cells were left stirring
and incubated for 20 h. The cell-coated beads were then
collected and incubated in flasks on a shaker for 1–2 days
until cells became confluent on the beads. A fibrinogen-bead
solution (1 ml of cell-coated beads in media, 27% w/v
fibrinogen, and 0.5% w/v aprotinin) was then mixed with a
thrombin solution (8.3 U/ml thrombin) in each well at a
ratio of 5:4 fibrinogen-bead solution:thrombin solution. Gels
were allowed to set in the incubator for 20 min before
addition of basic EGM-2MV supplemented with growth fac-
tors of interest at specific concentrations. Media were
changed every 24 h, and gels were maintained for up to 7
days. Gels were rinsed with PBS and fixed with 4% parafor-
maldehyde before imaging for sprout quantification.
Sprout imaging
High resolution images of beads were captured at 100 and
400 magnification. Epifluorescence images were captured
on the same Olympus microscope. Confocal images were
taken using an upright Zeiss LSM510 META microscope
(Carl Zeiss Inc., Thornwood, NY, USA). Images were analyzed
using IPLab 3.7 (Scanalytics, Rockville, MD, USA). Fluores-
cence images were background corrected using the rolling
ball script (8). Individual cells were segmented by intensity,
and the area of segmented sprouting cells was measured.
Fluorescence values of sprouts were corrected by subtracting
the minimum background intensity value of the image. The
number of sprouts per bead and sprout lengths was manually
determined, where a sprout is defined as an extension
containing more than one cell.
VEGF labeling
VEGF-A isoform VEGF(165) (Biological Resources Branch of
the National Cancer Institute, Bethesda, MD, USA) was used
throughout these studies.
Fluorescence labeling of VEGF was achieved by using Alexa
Fluor 555 Microscale Protein Labeling Kit (Molecular Probes,
Eugene, OR). Labeling was conducted according to instruc-
tions provided in the kit. Briefly, a reaction mixture of 50 l
of a 1 mg/ml solution of VEGF, 5 l of 1 M sodium
bicarbonate, and an appropriate volume of reactive dye
solution calculated based on the protein molecular weight
was incubated at room temperature for 15 min. Labeled
protein was separated from unreacted dye by centrifugation
in gel resin, and labeled protein was collected into 400 l
sterile water. The degree of labeling and yield were deter-
mined according to equations provided in the kit instructions
before use. The bioactivity of labeled protein was confirmed
using a proliferation assay with MECs (see Supplemental Fig.
4). Labeled VEGF was used to determine VEGF concentra-
tions in the diffusion chamber experiments by quantification
of fluorescence as a function of distance and converting to
concentrations using the known VEGF degree of labeling.
Radiolabeled VEGF binding assay
The binding assay was performed according to described
methods for determining binding on living cells (9). MECs
were seeded at 5000 cells/cm2 in 24-well plates and grown to
70% confluence. Cell medium was changed to EGM-2MV
without VEGF and incubated overnight. Cells were rinsed
twice with PBS and preincubated with EBM-2 media contain-
ing a saturating concentration of basic fibroblast growth
factor (300 ng/ml) to saturate nonspecific heparin-sulfate
proteoglycans binding sites and 0.1% BSA for 4 h at 4°C to
reduce nonspecific binding to other sites. MECs were then
incubated in increasing quantities of 125I-VEGF (1–160 ng/
ml), and binding was allowed to equilibrate overnight at 4°C.
Cells were washed twice with PBS, lysed with trypsin, and
collected. Cells incubated with unlabeled VEGF were col-
lected and counted. Radioactivity of each sample was counted
using a gamma counter and normalized to cell number.
Nonspecific VEGF binding was determined by incubation
with a 200-fold excess of unlabeled VEGF over labeled VEGF
(9–12). The number of VEGF molecules bound to MECs was
calculated from the raw count and the specific activity of the
batch of 125I-VEGF used in the assay.
Quantification of VEGF binding using fluorescence
resonance transfer technique (FRET)
MECs were labeled with 5-hexadecanoylaminofluorescein
(HEDAF) as the donor fluorophore. One milliliter of HEDAF
at a concentration of 10 mg/ml in DMSO was diluted 10-fold
in EGM-2MV, and the media were filtered to remove precip-
itates. The filtered HEDAF-media were diluted with media to
a total volume of 25 ml. MECs cultured to confluence in 75
cm2 flasks were incubated with 15 ml of the diluted HEDAF-
media for 3 h at 37°C and 5% CO2.
Labeled cells were collected and replated at a density of
5000 cells/cm2 in 96-well tissue culture plates overnight in
EGM-2MV without VEGF. The cells were rinsed twice with
PBS before incubation with Alexa 555-labeled VEGF for 30
min at 4°C to prevent internalization. VEGF binding was
determined by quantifying fluorescence using a Synergy HT
Microplate Reader (BioTek Instruments, Winooski, VT, USA)
fitted with appropriate wavelength filters. Cells were excited
at the excitation wavelength of the donor (488 nm), and
fluorescence was monitored at the emission wavelength of the
acceptor (565 nm). Fluorescence was also determined with
unlabeled cells and labeled VEGF to determine autofluores-
cence, and labeled MECs with labeled BSA to determine
nonspecific fluorescence. Autofluorescence and nonspecific
fluorescence values were subtracted to determine specific
fluorescence resulting from VEGF binding. Fluorescence
values were normalized to cell number and then correlated to
bound VEGF determined as a function of VEGF concentra-
tion from classic radiolabeled binding assays (section on
radiolabeled VEGF binding assay) to obtain the actual quan-
tity of VEGF bound by cells in the gels.
Scaffold fabrication
Mixtures of poly(lactide-coglycolide) (PLG; 85:15, intrinsic
viscosity0.8 dl/g; and 75:25, intrinsic viscosity0.26 dl/g;
Alkermes, Cambridge, MA, USA) microspheres (diame-
ter5–100 m) formed by standard double emulsion were
lyophilized with or without VEGF (Biological Resources
Branch of the National Cancer Institute) in a solution of
MVM alginate, a high-M-containing alginate, (5% of total
polymer mass; ProNova, Oslo, Norway) as described previ-
ously (13). Each scaffold layer containing 3 mg of PLG total
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and 50 mg of salt (250 md425 m) was mixed separately
and then manually compacted on top of each other, and
finally compressed to form a single scaffold (4.7 mm in
diameter, 3 mm total thickness). Scaffolds were then gas-
foamed and particulate-leached as described previously (14,
15). Total protein loaded after fabrication was 1.5 g of VEGF
in scaffold layer 1 and 3 g VEGF in scaffold layer 2.
Analysis of VEGF distribution
Scaffolds were fabricated as described above using Alexa
Fluor 488-conjugated BSA (Molecular Probes, Carlsbad, CA,
USA) in place of VEGF to examine the spatial distribution of
incorporated protein. Scaffolds were imaged using a Leica
MZFL III stereodissecting fluorescence microscope (Leica
Microsystems, Bannockburn, IL, USA).
Quantification of VEGF release kinetics
VEGF release kinetics from each layer of the scaffold were
determined using 125I-labeled recombinant human VEGF
(Perkin Elmer, Boston, MA, USA) as a tracer (15). Scaffolds
were fabricated as described with the addition of 0.11 Ci
radiolabeled VEGF mixed with the bulk quantity of unlabeled
VEGF. The total radioactivity of each scaffold layer (n4) was
counted in a gamma counter before incubation at 37°C in
PBS containing Ca2 and Mg2. At specific time points, the
radioactivity of the release solution was measured using a
WIZARD Automatic Gamma Counter (Perkin Elmer). Cumu-
lative VEGF released from the scaffold at each time point was
calculated as a percentage of total protein incorporated.
Mathematical modeling
The mathematical model described the VEGF profile as a
result of diffusion, release from the scaffold, and degradation.
The governing equation of the VEGF concentration, c, in
each of the two layers of the scaffold was
ci
t
 DV2ci krcoi kdci ; i  1,2
where the index i refers to the layer. The diffusion coefficient
of VEGF, DV  7.0  10
7 cm2/s, was determined by fitting
experimental data on VEGF diffusion. VEGF generation was
expressed as the product of the release rate, kr , and the initial
concentration in the layer at implantation, coi . VEGF release
was approximated to have two linear regions: a quick release
in the first 2 days and a slower subsequent release based
profiles of VEGF release from this scaffold system
(kr2.310
6 s1 during the first 2 days and 4.7107 s1
thereafter). The VEGF degradation rate (kd2.3110
4 s1)
was determined experimentally from an in vitro bioactivity
assay. The steady-state system was solved in COMSOL Mul-
tiphysics using the 2-D axial symmetric diffusion analysis tool
with a direct UMFPACK method.
Mouse model of hindlimb ischemia and scaffold
implantation
Layered scaffolds were implanted in 7- to 8-wk-old SCID mice
(Taconic, Hudson, NY, USA) that had undergone unilateral
ligation of hindlimb blood vessels to create a severe model of
hindlimb ischemia (16). Briefly, animals were anesthetized by
intraperitoneal injection of a ketamine and xylazine cocktail.
The entire hindlimb was shaved and sterilized before an
incision was made through the dermis. The external iliac
artery and vein and the femoral artery and vein were ligated
using 5–0 Ethilon (Ethicon, Somerville, NJ, USA). The vessels
were severed between the ligation points, and a layered
polymer scaffold was implanted with an orientation such that
layer 1 was directly over the sites of ligation and layer 2
extended into the muscles of the inner thigh.
Laser Doppler perfusion imaging (LDPI)
Measurements of the ischemic/normal limb blood flow ratio
were performed on anesthetized animals (n5) using a LDPI
analyzer (Perimed AB, Stockholm, Sweden). Perfusion mea-
surements were obtained by scanning entire hindlimbs. To
minimize variability due to ambient light and temperature,
the index was expressed as the ratio of ischemic to nonisch-
emic limb blood flow.
Micro-computed tomography (CT) imaging and analysis
After euthanization, the vasculature of animals was first
flushed with warm 0.9% heparinized saline (100 U/ml) and
then pressure fixed by flushing with 10% formalin through
the left ventricle. Formalin was cleared using heparinized
saline just before injection of a 9:1 mixture of the catalyst and
contrast compound (Microfil MV-122, Flow Tech, Carver,
MA, USA). Specimens were stored at 4°C in a humid chamber
overnight to allow the contrast agent to polymerize. Dissected
hindlimbs were fixed and then decalcified in a formic acid
solution (Cal-Ex II, Fisher Scientific, Pittsburgh, PA, USA).
Samples were rinsed and stored in 10% formation at 4°C until
imaging.
Hindlimb samples were imaged at high resolution (CT
40; Scanco Medical, Bassersdorf, Switzerland) with the scan-
ner set to a voltage of 55 kVp and a current of 145 A.
Specimens were scanned at a voxel size of 30 m, and a
threshold of 100 was applied based on visual interpretation of
thresholded 2-D tomograms.
Statistical analysis
Mean values are shown with error bars indicating the sd,
unless indicated otherwise. Statistical analysis was performed
by Student’s t test, where P  0.05 denotes statistical signifi-
cance.
RESULTS
To determine the quantitative relation between
VEGF(165) presentation and angiogenesis, an in vitro
3-D model (6) was used to quantify the relation be-
tween the level and direction of sprouting, the initial
stage in angiogenesis, and VEGF concentration and
gradient. MECs on beads embedded in a fibrin gel were
induced to undergo angiogenic sprouting in response
to VEGF in the media (Fig. 1a) at VEGF concentrations
that elicited a sprouting response, and sprouting was
directly proportional to the concentration of VEGF
(Fig. 1b). The concentrations of VEGF noted in this
study to significantly effect sprouting are within the
same range as previously reported (6, 7, 17). To quan-
tify the relation between VEGF gradients and sprout-
ing, the sprouting assay was performed in a diffusion
chamber that created specific gradients of VEGF across
the gel (see Supplemental Fig. 1). In general, higher
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levels of sprouting were observed from cells at high
VEGF concentrations near the VEGF source in the
chamber (Fig. 1c), as expected. Strikingly, quantifica-
tion revealed that the proportion of sprouts aligned
with the gradient was highest for cells close to the VEGF
source and thus experiencing a combination of a high
VEGF concentration and gradient (Fig. 1d). At dis-
tances farther from the VEGF source, sprouting was still
observed, but the sprouts that formed showed no
directional preference. Repeating this experiment for
MECs in the presence of a high VEGF concentration
without a gradient resulted in no preferential sprout
alignment (Fig. 1d).
To further investigate VEGF control over sprout
directionality, the sprouting assay was performed in the
diffusion chamber under different source concentra-
tions of VEGF (30, 100, and 300 ng/ml). The resulting
concentrations of VEGF within the fibrin gel were
determined in parallel. Quantification of sprouting
under these conditions revealed maximum sprouting at
a VEGF concentration of 100 ng/ml (Fig. 1e). The
presence of a VEGF gradient was critical to MEC sprout
alignment, and cells were able to align along a VEGF
gradient even at low concentrations. However, align-
ment began to decrease at VEGF concentrations 	250
ng/ml (Fig. 1f ), possibly due to VEGF receptor satura-
Figure 1. Endothelial cell sprouting in response to VEGF. a) Representative image of a bead with a MEC sprout (arrow). Sprout
consists of 	1 connected MECs that have migrated from bead into fibrin gel. Scale bar  100 m. b) MECs were seeded on
microcarriers embedded in fibrin gel and cultured with 0–100 ng/ml of VEGF added to media. Sprouting was quantified after
5 days (n4, 	30 beads/sample). Sprouting increased with increasing concentrations of VEGF. Statistical significance of P 
0.05 for all conditions, except where indicated by NS where P 	 0.05 relative to 10 and 50 ng/ml conditions. c) MEC sprouting
was quantified in a chamber where VEGF was provided on 1 side of the fibrin gel and allowed to diffuse across, creating a
gradient of VEGF. Number of sprouts per bead was counted in all beads within 1.0 mm of VEGF source after 5 days (n3, 	50
beads/sample). Level of sprouting decreased with increased distance away from VEGF source. Error bars  se. * Indicates
statistical significance from conditions marked by **, P  0.05. d) Angle of extension of a sprout from a bead (i.e., alignment
of a sprout along a gradient) was measured according to the assigned axes in a nongradient control and in categories of
increasing distance from the VEGF source: 0–0.2 mm, 0.2–0.4, 0.4–0.6, 0.6–0.8, 0.8–1.0, and 	1.0 m. Sprouts were analyzed
after 5 days (n3, 	50 beads/sample). Sprouts preferentially aligned along the gradient, with more sprouts closer to the VEGF
source. MEC sprouting (e) and alignment (f ) were quantified in a diffusion chamber with varying VEGF source concentrations:
10, 100, and 300 ng/ml. g) Dependence of sprouting on slope of gradient was determined in diffusion chamber sprouting assay
using the midrange VEGF source concentration (100 ng/ml) that elicited a maximal sprouting response. Guidance of sprouting
directionality occurs optimally with a gradient 	25 ng/ml per mm.
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tion. Optimal sprout alignment occurred in the pres-
ence of a gradient 	25 ng/ml per mm (Fig. 1g).
A FRET technique (18) was next developed to quan-
tify VEGF binding upon individual sprouting MECs,
and to directly examine the relation between actual
VEGF binding and the decision of individual cells to
participate in sprout formation. FRET is widely used to
examine nanoscale interactions of molecules (18) in
3-D but does not typically provide information regard-
ing the specific numbers of interactions. In contrast,
classic radiolabeled receptor binding assays (9, 10) are
used to quantify ligand binding to cell receptors, but
this technique is not amenable to real-time cell pro-
cesses in 3-D culture. Parallel analysis of cells in 2-D
culture, with both FRET measurements of VEGF bind-
ing and quantification of iodinated VEGF binding to
cells, allowed calibration of the FRET signal to actual
numbers of bound VEGF molecules (see Supplemental
Fig. 2). The radiolabeled receptor binding assay dem-
onstrated saturation between 40–100 ng/ml VEGF,
with a receptor density of 2.3  105 receptors/cell (see
Supplemental Fig. 2a). FRET was performed by label-
ing MECs with a lipophilic donor fluorescein dye, while
VEGF was labeled with an acceptor rhodamine analog.
The calibration curve allows one to calculate the num-
ber of VEGF molecules bound and taken up by sprout-
ing MECs, based on the specific fluorescence intensity
of cells in the assay (Fig. 2a). In general, both VEGF
binding and sprouting increased with escalation of
VEGF availability in the gel (Fig. 2b). The difference in
VEGF binding between tip and nontip cells decreased
as VEGF concentration in the media was increased
(Fig. 2c).
A mathematical model of VEGF distribution in vivo
was used to design a system capable of delivering VEGF
in a spatial concentration gradient within the range
where VEGF is able to both initiate and spatially control
angiogenesis. Inputs to this model included the exper-
imentally determined diffusion coefficient, half-life,
and cellular uptake of VEGF (see Supplemental Fig. 3).
This model led to a layered PLG scaffold design, in
which the scaffold consisted of two layers with differen-
tial VEGF loading in each layer (1.5 g in layer 1 and 3
g in layer 2). Incorporation of fluorescently labeled
protein into scaffolds showed that the protein re-
mained compartmentalized at the completion of the
fabrication process (Fig. 3a). VEGF release was deter-
mined using radiolabeled VEGF, and the release kinet-
ics varied based on the total loading of VEGF, resulting
in different quantities of VEGF released from each
layer of the scaffold (Fig. 3b). The predicted VEGF
concentrations in tissue resulting from this delivery
system fell within the desired active range (Fig. 3c), and
appropriate orientation of the system in ischemic hind-
limbs of mice could lead to a VEGF gradient that would
drive vessels to extend in the desired direction. At
steady state, a steep gradient of 40 ng/ml per mm
existed along the tissue–scaffold interface, with a max-
imum tissue concentration of 120 ng/ml and a mini-
mum concentration of 38 ng/ml (Fig. 3c). The gradi-
ent flattened with increasing distance away from the
scaffold, but a gradient of VEGF in the tissue was
maintained at steady state up to 1 mm away from the
scaffold (Fig. 3c).
Layered scaffolds capable of delivering spatially con-
trolled gradients of VEGF were implanted in a mouse
model of hindlimb ischemia to assess their ability to
drive angiogenesis and restore perfusion. The layered
scaffolds were implanted such that the VEGF gradient
extended perpendicularly across the ischemic limb, in
the desired direction for new vessel extension. Controls
included implantation of blank scaffolds (no VEGF),
and scaffolds that had the same total quantity of VEGF
evenly distributed throughout their volume (leading to
similar VEGF concentrations in tissue, but little to no
VEGF gradient in the desired direction). Spatial VEGF
delivery led to extensive formation of new vessel net-
works in the ischemic limbs (Fig. 3d), while control
conditions exhibited less extensive vessel networks (Fig.
3e), as indicated by micro-CT imaging of vascular casts.
Analysis of vasculature revealed higher vessel densities
in VEGF control and layered VEGF conditions than in
the blank scaffold condition. In hindlimbs implanted
with blank scaffolds, the sites of ligation were not fully
Figure 2. VEGF binding on sprouting MECs in vitro. a) Representative FRET image of labeled MECs (green) in a sprouting assay
with labeled VEGF (red) shows energy transfer after excitation of donor fluorophore. Images of sprouts bound with VEGF were
analyzed to quantify VEGF binding in individual sprouts via use of the calibration between FRET and iodinated VEGF binding.
Scale bar  50 m. b) Histogram of VEGF bound/cell and the resultant extent of sprouting. Fluorescently labeled VEGF was
added to media in a MEC sprouting assay (n4, 	200 beads/sample). Increasing concentrations of VEGF were used: 10, 25,
50, and 100 ng/ml. As VEGF availability increased, number of sprouts increased, and average VEGF bound to sprouting cells
increased. c) VEGF binding specifically to tip cells vs. nontip MECs participating in sprouting was quantified. Overall, tip cells
bound more VEGF than nontip cells, but this difference decreased with increasing VEGF availability. *P  0.05.
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bridged and enlargement of collateral vessels (anterior
tibial artery and vein, lateral marginal artery and vein)
occurred, indicating occluded blood flow in nearby
arteries. In vascular casts of hindlimbs with layered
VEGF scaffold implantation, the sites of ligation were
bridged by a large conductance vessel, re-establishing
the femoral artery. Additionally, there were fewer en-
larged vessels around the site of the spatial VEGF
delivery, and the architecture of major arteries and
veins (hypogastric, great saphenous, anterior tibial,
lateral marginal) was clearly visible with close resem-
blance to that of normal hindlimbs. The vascular
network in the area of layered scaffold implantation
showed vascular organization corresponding to the
delivered VEGF gradient, where vessel density in-
creased away from the sites of ligation.
Importantly, spatial VEGF delivery resulted in rapid
restoration of hindlimb blood flow to normal levels by
week 2 (Fig. 3f ). Control animals implanted with a
blank scaffold had a small increase in perfusion to 46

5% of the normal level, whereas VEGF delivery without
spatial control led to perfusion levels of 63 
 16% by
this time. The varying ability of the experimental
interventions to increase hindlimb blood flow was
reflected in observed levels of hindlimb ischemia sever-
ity (Fig. 3g). Severe necrosis occurred with blank and
uniform VEGF delivery, and the integrity of ischemic
hindlimbs declined over time in these conditions. The
Figure 3. Spatially controlled VEGF delivery in vivo. a) Scaffolds with spatially compartmentalized VEGF were designed, based
on the results of mathematical models of VEGF release needed to generate appropriate tissue concentrations and gradients.
Fluorescently labeled protein was used to examine incorporation into individual compartments of layered scaffolds. After
fabrication, loaded protein remained confined to each layer. Dotted lines indicate border of entire layered scaffold and
separation between layers. b) VEGF release from each layer was determined using 125I-VEGF incorporated as a tracer in layer 1
or layer 2. Overall release profile is similar in each layer, with an initial burst of VEGF followed by a steady release. Quantity of
VEGF released was proportional to total mass of VEGF incorporated in each layer (1.5 g in layer 1 and 3 g in layer 2). c)
Predicted VEGF distribution in ischemic hindlimbs, with scaffold orientation as indicated in insert. Scaffold placement was
designed to create a VEGF gradient that extended away from the femoral artery/vein (X) into muscle tissue (pink), guiding new
capillaries to orient down ischemic limb. VEGF concentrations in a layered scaffold were modeled and solved in COMSOL, and
steady-state VEGF concentrations, predicted to be reached after 30 min, are shown. Tissue VEGF concentrations across scaffold
edge are plotted at distances away from edge: 0, 0.5, 1.0, 1.5, and 2.0 mm. d, e) Micro-CT images of vascular casts show
architecture of vascular network in ischemic hindlimbs. Layered VEGF scaffold implantation (d) resulted in more normalized
vasculature where the femoral artery and vein are completely bridged by a large vessel and the hypogastric vein is clearly visible
without significant collateral arteriogenesis, while control scaffold (no VEGF) implantation (e) did not result in complete
bridging of the ligation sites (arrows) and collateral vessels were enlarged. Scale bar 1 mm. f ) Recovery of hindlimb perfusion
in animals that had undergone unilateral vessel ligation and scaffold implantation as monitored by LDPI (n5). Increase in
perfusion over baseline after vessel ligation is plotted. Experimental conditions examined were control (no VEGF) scaffolds,
scaffolds with 4.5 g VEGF evenly distributed, and spatially controlled VEGF delivery. Complete reperfusion was observed with
spatially controlled presentation of VEGF. *P  0.05 for even and layered VEGF conditions compared to blank, **P  0.05 for
layered VEGF compared to blank, and ***P  0.05 for layered VEGF compared to blank and even VEGF. g) Ischemic hindlimbs
were examined to determine the severity of hindlimb ischemia postligation and scaffold implantation. Degree of hindlimb
severity was categorized as normal compared to the unligated limb, or having one necrotic toe, multiple necrotic toes, or a
necrotic foot. Hindlimb ischemia progressed through week 6 in animals implanted with blank control scaffolds (B/B). Animals
with evenly distributed VEGF (V) had lower levels of ischemic severity compared to control, but necrosis continued to progress
through week 6. Spatially regulated VEGF presentation (V/V) reduced limb necrosis at week 1, and improvements in hindlimb
ischemia occurred over time, with a resultant prevention of severe necrosis.
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rapid restoration of blood flow to ischemic hindlimbs
achieved with spatial VEGF delivery had a significant
protective effect against severe hindlimb necrosis and
improved hindlimb integrity over time (Fig. 3g). Since
blood flow largely returned to normal by week 2, toes
that initially appeared necrotic in this group also re-
turned to normal color by week 6.
DISCUSSION
The results from these in vitro studies further elucidate
and quantify the role of VEGF(165) in controlling the
biological process of angiogenesis. Previous in vitro
work has shown that VEGF not only enhances endothe-
lial cell survival, proliferation, and migration (19, 20)
but that VEGF is also a potent chemoattractant (21)
and provides directionality to sprouting endothelial
cells (22). In addition to supporting previous findings,
data from these studies show VEGF binding in longer
term cultures was higher than levels noted at saturation
in 2-D culture (Fig. 2b; also see Supplemental Fig. 3c),
suggesting that either VEGF exposure or 3-D culture
led to increased receptors on MECs. Therefore, quan-
tification of VEGF binding in an in vitro 3-D model of
sprouting angiogenesis is essential to understanding
VEGF control of this process.
Importantly, the data from 3-D culture indicate
VEGF control over sprouting and its direction results
from heterogeneity in the ability of MECs to bind and
respond to VEGF. Although no sprouting was noted
when 8  104 molecules VEGF were bound per cell
(Fig. 2b), there did not appear to be one threshold of
binding where all cells sprouted. This finding suggests
that two thresholds may guard MEC activation and
sprout initiation. Quantification of VEGF binding also
revealed heterogeneity in VEGF binding among sprout-
ing cells, as the cells leading the sprout (tip cells) had
a statistically significantly increase in VEGF binding as
compared to the cells in the body of the sprout (nontip
cells). This finding supports previous in vivo studies
showing that vascular sprouts are composed of distinct
populations of nontip cells led by migrating tip cells
(23). Sprout alignment along a VEGF gradient may be
facilitated by this ability of tip cells to bind higher
numbers of VEGF molecules and thus become activated
at lower VEGF concentrations and detect subtle differ-
ences in VEGF concentration as present in VEGF
gradients. As VEGF concentration in the media in-
creased, the difference between VEGF binding on tip
and nontip cells decreased (Fig. 2c), presumably due to
cell receptors becoming saturated, and this contributed
to the loss of sprout alignment at high VEGF concen-
trations.
The conclusions drawn from the data suggest there is
a both a minimum concentration and gradient of VEGF
required for control over sprouting and its direction.
Low VEGF concentrations may be insufficient to acti-
vate MECs toward sprout formation, while high VEGF
concentrations may saturate cell receptors and disrupt
cell guidance. These studies indicate that control over
angiogenesis is likely most effective when VEGF is
present in a gradient, with a maximum concentration
near 100 ng/ml for optimal initiation of sprouting and
control over directionality.
An effective in vivo growth factor delivery system was
created based on this quantitative understanding of the
role of VEGF in controlling angiogenesis in vitro. SCID
mice that had undergone unilateral external iliac and
femoral artery ligation were used as a severe model of
hindlimb ischemia because unlike normal mice, these
animals are not able to fully recover hindlimb perfusion
without intervention (24). The results from implanta-
tion of devices with uniform VEGF distribution in
ischemic hindlimbs of SCID mice were consistent with
past studies (16, 24) where hindlimb blood flow was
enhanced above control, but did not completely restore
perfusion to normal levels. Interestingly, hindlimbs
implanted with devices designed to deliver a spatial
VEGF gradient based on in vitro modeling showed
accelerated recovery from hindlimb ischemia (Fig. 3f ),
and this result supports the importance of VEGF tissue
gradients in addition to VEGF concentrations in form-
ing functional vessel networks.
The in vivo results highlight the importance of
accelerated recovery from hindlimb ischemia to pre-
vent the incidence of severe necrosis (Fig. 3g). These
results also indicate that spatial VEGF delivery may have
led to the formation of more normalized vascular
networks, allowing accelerated restoration of perfusion.
The amplified reperfusion described in this study was
likely due to both the sustained delivery of VEGF and
the spatially controlled presence of VEGF. Spatially
controlled VEGF delivery may direct the initial forma-
tion of a more organized vascular network, reducing
the need for significant remodeling and enabling effi-
cient network formation.
In these studies, we have demonstrated that a quan-
titative understanding of the growth factor driven pro-
cess of angiogenesis can be used to rationally design
delivery vehicles, leading to improved therapeutic out-
comes. This integration of quantitative biological mea-
surements, mathematical modeling, and device design
has great potential utility not only for therapeutic
angiogenesis but also for other tissue regeneration
strategies using growth factor delivery, and highlights
the importance of interdisciplinary approaches in de-
signing molecular therapies.
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